I don't remember that. Do you have the link?
RC actually applied for the approval of Anatabloc as a food supplement in Netherlands, so, basically in Europe. It was rejected in January 2016 which was about 6 months before the Phase 1 clinical trial result was released. It was rejected because the committee thought anatabine was not safe.
That application was somewhat questionable. RC supplied Hashimoto's thyroiditis research paper as an evidence of safety. In that paper the ratio of negative side-effect was somewhat high (in my opinion, compared to the testimonies of the users, and yes, I trust those testimonies because I was one of the users).
I wonder why RC did not wait till Phase 1 trial was finished. If so, the committee would have no ground to reject because Phase 1 result was 'safe and well tolerated.' Maybe RC was impatient because of short of money? Anyway, they could have reapplied by including the new safety result, but they applied for the bankruptsy instead.
